Can Changes in Driving Habits Predict Cognitive Decline in Older Adults?

GAP-Net site Knight ADRC at Washington University in St. Louis received two grants to determine whether driving changes can identify people with mild and very mild cognitive impairment, and maybe even identify people in the earliest stage of Alzheimer’s disease. Every day in the U.S. in 2018, motor vehicle crashes killed more than 20 people […]

Read more »

Lilly’s TRAILBLAZER-ALZ 2 Trial is Partnering with the Global Alzheimer’s Platform Foundation® to Shatter the Slow Completion Timeframes of Alzheimer’s Clinical Trials

TRAILBLAZER-ALZ 2 is the second study of donanemab, which showed favorable results in an earlier trial. Washington, DC (March 13, 2021) – Eli Lilly and Company, a leader in Alzheimer’s research for over 30 years, is partnering with the Global Alzheimer’s Platform Foundation® (GAP) to accelerate recruitment services and expand the number of clinical research […]

Read more »

U.S. Trials for Alzheimer’s “Seaweed Drug” Oligomannate Recruiting Participants

GAP-Net Site, The Cognitive and Research Center of New Jersey, talks about their participation in the GREEN MEMORY trial. The Alzheimer’s Drug, Oligomannate, approved in China and derived from seaweed, is now being studied in the U.S. in a Phase 3, multi-center clinical trial that is actively recruiting participants.  Oligomannate, a drug made from seaweed […]

Read more »

This Alzheimer’s Drug Made From Seaweed got Approved in China. Now it’s Being Tested in N.J.

GAP President John Dwyer spoke about the Green Valley clinical trial’s success in China, which is now being tested in North America. A new drug extracted from seaweed and inspired by traditional Chinese medicine has come to the United States, where researchers hope it will provide the breakthrough in Alzheimer’s treatment that has eluded us […]

Read more »

We Need an Operation Warp Speed for Alzheimer’s and Dementia

GAP Chairman, George Vradenburg, and The Women’s Alzheimer’s Movement founder, Maria Shriver, co-wrote a piece on what the Biden Administration needs to do to start fulfilling their promises made to Alzheimer’s patients and researchers. No president has entered the White House with as clear a focus on Alzheimer’s disease as Joe Biden. The commitment and […]

Read more »

Jordan Man Takes Part in Alzheimer’s Research

GAP-Net site Clarity Clinical Research issued the first treatment to volunteer Mark Cornue in the GREEN MEMORY study. Last week, Clarity Clinical Research administered the first research treatment in the world for the Green Memory study to Mark Cornue, a local Jordan resident and Alzheimer’s patient. The Green Memory study is a noninvasive Alzheimer’s disease clinical trial […]

Read more »

Clinical Trial Volunteers Need to Help Make Alzheimer’s a Thing of the Past

GAP-Net site Kerwin Medical Center’s Citizen Scientist, Dominic Morello, a caregiver for his father with Alzheimer’s, wrote an Op-Ed on how this generations Alzheimer’s patients can make the disease a thing of the past. There are more than 100 potential Alzheimer’s treatments in the pipeline, but the majority of clinical trials for potential Alzheimer’s therapies are delayed due to enrollment […]

Read more »

2020 Citizen Scientist Awards: Elected Official Recognition

Some of our 2020 Citizen Scientist National Honorees were congratulated by their local officials on their social media pages. We have compiled the links here. Dr. Collins Lewis, Cornerstone Award National Honoree Missouri Senator Roy Blunt Missouri Senator Karla May Congress Women Amy Wagner Brentwood, Missouri Mayor David Dimmitt Representative Matt Willhite, Collaborator Award National […]

Read more »

Dr. Collins Lewis, 2020 Citizen Scientist Cornerstone Award National Honoree, Congratulated by Missouri State Senator

Dr. Collins Lewis, 2020 Citizen Scientist Cornerstone Award National Honoree, from GAP-Net site Knight Alzheimer Clinical Trial Unit at Washington University in St. Louis was congratulated for his participation in Alzheimer’s disease clinical trials by Missouri senator Roy Blunt. Dear Dr. Lewis, It is my pleasure to join your family, friends, and colleagues in congratulating […]

Read more »

Collaboration Between the FDA and Industry is Essential to Foster Innovation in Alzheimer’s Treatments

GAP Chairman George Vradenburg and Dr. Jeffrey Cummings co-wrote an opinion piece about why the FDA and Alzheimer’s disease scientists, regulators, and business leaders must work together to achieve a safe, effective drug for Alzheimer’s treatment. As the Food and Drug Administration moves closer to a decision about whether to approve a promising new Alzheimer’s […]

Read more »

What Operation Warp Speed can Teach us About Curing Diseases

GAP-Net site JEM Research Institute talks about what COVID-19 trials and vaccines tell us about Alzheimer’s disease trials, and the need for volunteers. The White House hopes to vaccinate 100 million people in the first 100 days of the new administration. That would be a historic accomplishment from the virus to the vaccine in less […]

Read more »

Tony Bennett’s Alzheimer’s Diagnosis Again Puts Spotlight on Link Between Music, Memory

GAP-Net site, the University of California Irvine’s UCIMind is quoted about how music may play a role in preserving memory and delaying Alzheimer’s disease. IRVINE (CBSLA) — On Monday, it was revealed that legendary singer Tony Bennett has been battling Alzheimer’s disease for more than four years. On Monday, it was revealed that singer Tony Bennett, seen here […]

Read more »

National Institutes of Health Awards Cleveland Clinic $6.7 Million Grant to Evaluate Impact of High-Intensity Exercise in Preventing Alzheimer’s Disease

GAP-Net site Cleveland Clinic was awarded a grant by the NIH to evaluate if high-intensity exercise can prevent development of Alzheimer’s disease. The National Institutes of Health has awarded Cleveland Clinic a $6.7 million grant to evaluate if high-intensity exercise can prevent development of Alzheimer’s disease. The five-year study will assess the effect of home-based indoor cycling […]

Read more »

STATEMENT: ELI LILLY’S PHASE 2 DONANEMAB STUDY RESULT IS CAUSE FOR CELEBRATION

Statement by GAP President John Dwyer on the results of the Phase 2 trial for Donanemab: We congratulate Eli Lilly on the results of the Donanemab clinical trial showing it significantly slowed the cognitive and functional decline of people with mild Alzheimer’s. This is a major step towards discovery of a disease modifying therapy. Alzheimer’s […]

Read more »

STATEMENT: BIOGEN AND APPLE PARTNERSHIP SPEEDS SEARCH FOR ALZHEIMER’S TEST; SHOULD PRIORITIZE DIVERSITY

Statement by Global Alzheimer’s Platform Foundation (GAP) President John Dwyer on today’s announcement that Biogen and Apple are partnering on an observational study to investigate the role Apple Watch and iPhone could play in screening for mild cognitive impairment (MCI):  Today’s announcement by Biogen and Apple marks a significant step on the path to early […]

Read more »

Aducanumab for Alzheimer’s: One Drug, Two Results

A clinical trial participant from #GAPNet site, JEM Research, talks with her husband about their experience in the Aducanumab trial, which is pending approval by the US Food and Drug Administration by March 2021. There are currently more than five million Americans living with Alzheimer’s disease… and despite ongoing research, there has been no new […]

Read more »
To top